Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of-concept Trial
Thérapie(2012)
摘要
Objective. To test the modulation of farnesoid X receptor activity on the replication of hepatitis C virus in chronically infected patients. Methods. This is a proof-of-concept trial that was approved by the ex-French Agency for the Safety of Health Products (ex-Afssaps [currently ANSM]) and an ethics committee. It has started in January 2010. This one-arm, open-label study examines the safety and efficacy of the oral administration of guggulsterone. The main outcome measure will be the assessment of blood viral loads. Results. We planned to enrol 15 genotype 1-infected patients that failed a first-line therapy. Conclusion. We think guggulsterone might be an effective therapeutic option for HCV genotype 1 patients who do not respond well to first-line therapy.
更多查看译文
关键词
clinical trial,farnesoid X receptor,hepatitis C,proof of concept
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要